Sanofi/Merck Launch First 6-In-1 Combo Vaccine In US After Two-And-A-Half Year Supply Buildup
Executive Summary
Five years after European licensure and launch, and 30 months after FDA approval, Vaxelis enters the US market offering an advantage of fewer shots than current pentavalent vaccines for protection against six diseases in children six weeks to four years old.
You may also be interested in...
CDC Advisors Like Pfizer’s COVID Vaccine For Adolescents But Are Less Sure Of Coadministration
Without giving ACIP a chance to vote on the change or providing additional data, CDC announces new guidance allowing coadministration of COVID-19 vaccines with other immunizations. Needless to say, the decision raised a few eyebrows.
Sanofi Pasteur Head Loew On The Vaccine Unit's Future Growth Drivers
David Loew talked to Scrip about the next-generation meningococcal vaccine candidate MenQuadfi and a monoclonal antibody that may be the first RSV treatment for infants.
GSK’s Shingrix Vaccine Can Reach Millions More
The shingles vaccine could potentially be used in about three million immunocompromised people, according to GSK, but CDC’s advisory committee will weigh in with recommendations.